Clinical Trial Update: Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating reduced-dose carboplatin-doublet chemotherapy plus cemiplimab versus cemiplimab alone in treatment-naive older and frail patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cemiplimab (cemiplimab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING